URGN
UroGen Pharma Ltd.
Approval
Confirmed
ZUSDURI
recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
232d ago
Jan 1, 2026
SEC 8-K
verified 2mo ago
Countdown card →